Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) EBITDA Margin: 2022-2025

Historic EBITDA Margin for bioAffinity Technologies (BIAF) over the last 4 years, with Sep 2025 value amounting to -155.47%.

  • bioAffinity Technologies' EBITDA Margin fell 7321.00% to -155.47% in Q3 2025 from the same period last year, while for Sep 2025 it was -150.61%, marking a year-over-year decrease of 6453.00%. This contributed to the annual value of -93.90% for FY2024, which is 21173.00% up from last year.
  • As of Q3 2025, bioAffinity Technologies' EBITDA Margin stood at -155.47%, which was up 20.13% from -194.65% recorded in Q2 2025.
  • Over the past 5 years, bioAffinity Technologies' EBITDA Margin peaked at 59.61% during Q2 2022, and registered a low of -166,806.19% during Q1 2023.
  • For the 3-year period, bioAffinity Technologies' EBITDA Margin averaged around -16,129.95%, with its median value being -139.37% (2025).
  • Per our database at Business Quant, bioAffinity Technologies' EBITDA Margin plummeted by 896,300bps in 2023 and then soared by 16,672,697bps in 2024.
  • Quarterly analysis of 4 years shows bioAffinity Technologies' EBITDA Margin stood at -68,902.77% in 2022, then spiked by 6,880,445bps to -98.32% in 2023, then slumped by 3,322bps to -131.53% in 2024, then slumped by 7,321bps to -155.47% in 2025.
  • Its EBITDA Margin stands at -155.47% for Q3 2025, versus -194.65% for Q2 2025 and -139.37% for Q1 2025.